A new prostate cancer (PCa) treatment called HyperAcute Prostate Cancer Immunotherapy has shown promise in a small number of patients. The therapy consists of two allogeneic PCa tumor cell lines modified to express alpha-Gal. These cell lines were chosen to provide a broad coverage of prostate cancer antigens. John Schieszer has the latest on the story in today’s Medical Minute.

Continue Reading